The research partnership between Tonix Pharmaceuticals and Columbia University in the US has been extended to serve the development of Covid-19 vaccines and therapies precision treatment techniques.

Additionally, Tonix Pharmaceuticals and Columbia University will analyse the immune responses of recovered or asymptomatic healthy subjects to Covid-19.

The partnership will also focus on in vitro T cell and antibody responses to the SARS-CoV-2 virus, which causes Covid-19.

The alliance intends to fill vital gaps in interpreting the detailed immune responses to Covid-19 and offer a base for customising vaccines and treatments to suitable people with precision therapeutic.

The researchers will evaluate the T cell and antibody responses in various ways, including at the cellular level by inducing T cells in vitro with CoV-2 antigens and by producing fully human monoclonal antibodies against SARS-CoV-2.

This study could lead to the isolation, characterisation and cloning of therapeutically significant fully human neutralising monoclonal antibodies to the virus.

Furthermore, the deoxyribonucleic acid (DNA) aptamer-based anti-idiotypes will be generated to specific monoclonal antibodies detected.

These aptamers could aid in identifying biomarkers for protective CoV-2 immunity and boost the design of precision medicine-driven Covid-19 vaccines.

Tonix Pharmaceuticals president and CEO Seth Lederman said: “Based on the progress and results of the initial phase of these projects, we are excited to expand our research collaboration with Columbia University on these precision medicine technologies and also to potentially develop new monoclonal antibody therapeutics.

“Data from this collaboration may provide a roadmap and tools to potentially guide the selection of appropriate individuals for Covid-19 vaccine trials and to help determine which vaccine is appropriate for each individual based on the condition of their immune system or other physiological features.”

In June last year, Tonix expanded its ongoing partnership with non-profit Southern Research to study T-cell immune responses to SARS-CoV-2.

Tonix has reported this June that the company will develop its TNX-102 SL as a potential therapy for Long COVID syndrome.